Sugi Predict

Sugi Predict / Compounds / SCHEMBL329840

SCHEMBL329840

SCHEMBL329840

O=C(NC(C(=O)O)C1CCCCC1)c1cnccn1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 1/20 0.54
▸ GAA P10253 1/20 0.51
▸ LMNA P02545 2/20 0.49
▸ LONP1 P36776 3/20 0.48
▸ PSMB11 A5LHX3 2/20 0.48
▸ PSMA7 O14818 2/20 0.48
▸ PSMB1 P20618 2/20 0.48
▸ PSMA1 P25786 2/20 0.48
▸ PSMA2 P25787 2/20 0.48
▸ PSMA3 P25788 2/20 0.48
▸ PSMA4 P25789 2/20 0.48
▸ PSMB8 P28062 2/20 0.48
▸ PSMB9 P28065 2/20 0.48
▸ PSMA5 P28066 2/20 0.48
▸ PSMB4 P28070 2/20 0.48
▸ PSMB6 P28072 2/20 0.48
▸ PSMB5 P28074 2/20 0.48
▸ PSMB10 P40306 2/20 0.48
▸ PSMB3 P49720 2/20 0.48
▸ PSMB2 P49721 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7857535 1.00 MAPT (0.54) MAPTGAALMNALONP1PSMB11
SCHEMBL3210060 0.95 MAPT (0.50) MAPTGAALMNALONP1PSMB11
SCHEMBL3210085 0.95 MAPT (0.50) MAPTGAALMNALONP1PSMB11
SCHEMBL8033800 0.88 MAPT (0.53) MAPTGAALMNALONP1PSMB11
SCHEMBL2411972 0.88 MAPT (0.53) MAPTGAALMNALONP1PSMB11
SCHEMBL10043293 0.88 MAPT (0.53) MAPTGAALMNALONP1PSMB11
SCHEMBL2411970 0.88 MAPT (0.53) MAPTGAALMNALONP1PSMB11
SCHEMBL13319446 0.86 MAPT (0.51) MAPTGAALMNALONP1PSMB11
SCHEMBL10044937 0.86 MAPT (0.51) MAPTGAALMNALONP1PSMB11
SCHEMBL7850086 0.86 MAPT (0.51) MAPTGAALMNALONP1PSMB11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2014203224-A1 PROCESS FOR THE PREPARATION OF TELAPREVIR AND ITS INTERMEDIATES RANBAXY LABORATORIES LIMITED (IN) 2014-12-24 — — WO claimed
CN-104558106-B Preparation method of medicine for treating hepatitis C 广东东阳光药业有限公司 2019-12-10 — — CN disclosed
CN-103145715-B Huge ring carboxylic acid and acyl sulfonamides as HCV replication inhibitors F·霍夫曼-罗须公司 2016-08-03 — — CN disclosed
WO-2014203224-A1 PROCESS FOR THE PREPARATION OF TELAPREVIR AND ITS INTERMEDIATES RANBAXY LABORATORIES LIMITED (IN) 2014-12-24 — — WO disclosed
CN-102020697-B Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication F. HOFFMANN-LA ROCHE LTD. (CH) 2014-10-29 — — CN disclosed
US-20130303547-A1 HCV Protease Inhibitors and Uses Thereof ABBVIE INC (US) 2013-11-14 — — US disclosed
US-8497275-B2 HCV protease inhibitors and uses thereof ABBVIE INC. (US) 2013-07-30 — — US disclosed
CN-103145715-A Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication HOFFMANN LA ROCHE 2013-06-12 — — CN disclosed
EP-2539320-A1 A PROCESS FOR THE PREPARATION OF SUBSTITUTED PROLYL PEPTIDES AND SIMILAR PEPTIDOMIMETICS Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patiëntenzorg (NL) 2013-01-02 — — EP disclosed
US-20120329704-A1 PROCESS FOR THE PREPARATION OF SUBSTITUTED PROLYL PEPTIDES AND SIMILAR PEPTIDOMIMETICS VERENIGING VOOR CHRISTELIJK HOGER ONDERWIJS WETENSCHAPPELIJK ONDERZOEK EN PATIEENTENZORG (NL) 2012-12-27 — — US disclosed
US-20080108632-A1 HCV PROTEASE INHIBITORS TAIGEN BIOTECHNOLOGY CO., LTD. (TW) 2008-05-08 — — US disclosed
CN-1938311-A Macrocyclic compounds as inhibitors of viral replication INTERMUNE INC (US) 2007-03-28 — — CN disclosed
EP-1749007-A2 MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION Intermune, Inc. (US) 2007-02-07 — — EP disclosed
CN-1889970-A Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication INTERMUNE INC (US) 2007-01-03 — — CN disclosed
EP-1680137-A2 MACROCYCLIC CARBOXYLIC ACIDS AND ACYLSULFONAMIDES AS INHIBITORS OF HCV REPLICATION Intermune, Inc. (US) 2006-07-19 — — EP disclosed
US-20050267018-A1 Macrocyclic compounds as inhibitors of viral replication HOFFMANN-LA ROCHE INC. 2005-12-01 — — US disclosed
WO-2005095403-A2 MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION INTERMUNE, INC. (US) 2005-10-13 — — WO disclosed
WO-2005095403-A2 MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION INTERMUNE, INC. (US) 2005-10-13 — — WO disclosed
WO-2005037214-A2 MACROCYCLIC CARBOXYLIC ACIDS AND ACYLSULFONAMIDES AS INHIBITORS OF HCV REPLICATION INTERMUNE, INC. (US) 2005-04-28 — — WO disclosed
WO-2005037214-A2 MACROCYCLIC CARBOXYLIC ACIDS AND ACYLSULFONAMIDES AS INHIBITORS OF HCV REPLICATION INTERMUNE, INC. (US) 2005-04-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120329704-A1 PROCESS FOR THE PREPARATION OF SUBSTITUTED PROLYL PEPTIDES AND SIMILAR PEPTIDOMIMETICS NGLY1, NPR3, NPR1 MAPT 3676/4885GAA 2547/4885LMNA 2443/4885
US-20130303547-A1 HCV Protease Inhibitors and Uses Thereof SERPINB1, PEPD, PREP MAPT 3158/4885GAA 71/4885LMNA 2562/4885
US-20080108632-A1 HCV PROTEASE INHIBITORS SERPINB1, HAVCR2, RNASE1 MAPT 3844/4885GAA 77/4885LMNA 4464/4885
US-20050267018-A1 Macrocyclic compounds as inhibitors of viral replication EIF2AK2, HAVCR2, ZC3HAV1 MAPT 4563/4885GAA 646/4885LMNA 625/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.